Ripertamab for the Treatment of Myasthenia Gravis

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Ripertamab for the Treatment of Myasthenia Gravis	Neoplasms by Site, Paraneoplastic Syndromes, Nervous System, autoimmune disease, autoimmune disorder of the nervous system, immune system disorder, myasthenia gravis, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, neuromuscular junction disease, paraneoplastic syndrome	Not yet recruiting	Phase 1 / Phase 2	2026-01-28		NCT07372807

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Zhongming Qiu	11

0 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
No products are listed yet.

Clinical trials